The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ, in patients with relapsed/refractory CLL.
Manish R. Patel
Research Funding - Infinity
Brad S. Kahl
Research Funding - Infinity
Steven M. Horwitz
Consultant or Advisory Role - Allos Therapeutics; Bristol-Myers Squibb; Celgene; Genzyme; Janssen; Johnson & Johnson; Kyowa Hakko Kirin; Millennium; Seattle Genetics
Research Funding - Allos Therapeutics; Celgene; Infinity; Kyowa Hakko Kirin; Millennium; Seattle Genetics
Anas Younes
Research Funding - Genentech; Gilead Sciences; Infinity; Novartis; Sanofi ; Seattle Genetics
Francine M. Foss
Consultant or Advisory Role - Celgene; Eisai; Millennium; Spectrum Pharmaceuticals
Research Funding - Infinity
Yasuhiro Oki
Research Funding - Infinity
Jennifer Sweeney
Employment or Leadership Position - Infinity
Stock Ownership - Infinity
Kerstin Allen
Employment or Leadership Position - Infinity
Stock Ownership - Infinity
Kerrie Faia
Employment or Leadership Position - Infinity
Stock Ownership - Infinity
Patrick Francis Kelly
Employment or Leadership Position - Infinity
Stock Ownership - Infinity
Ian Flinn
Consultant or Advisory Role - Infinity (U)
Research Funding - Infinity